The global pandemic has shown the world just how important the biotech industry really is with many stocks in the sector seeing gains based on innovative product launches with positive global impacts.
One biotech small cap may potentially become the next company to generate attention for targeting the year's most significant healthcare trends with multiple potential breakthrough developments! Products in development include a rapid Covid-19 test and a drug candidate that could give Epidiolex a run for its money in the $16.5 billion epilepsy treatment market.
The company has optimized the gold standard PCR diagnostic exam to make it what could be the world's fastest and most portable Covid-19 test, with results delivered in as little as 25 minutes!
Moreover, this advance in Covid-19 testing could potentially be ready to deploy before the end of the month, subject to pending European regulatory approval. This potential breakthrough is something to keep your eyes on as it could be a significant value creator for the company!
Read on to find out why this biotech stock could emerge as one of 2021's winners!
If you no longer wish to receive our emails, click the link below:
Unsubscribe
DailyMarketAlerts 315 Ridgedale Avenue #556 East Hanover, New Jersey 07936 United States
No comments:
Post a Comment